{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:08:59Z","timestamp":1740107339951,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Natalizumab (NTZ) and ocrelizumab (OCR) can be used for the treatment of relapsing\u2013remitting multiple sclerosis (RRMS). In patients treated with NTZ, screening for JC virus (JCV) is mandatory, and a positive serology usually requires a change in treatment after 2\u00a0years. In this study, JCV serology was used as a natural experiment to pseudo-randomize patients into NTZ continuation or OCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An observational analysis of patients who had received NTZ for at least 2\u00a0years and were either changed to OCR or maintained on NTZ, depending on JCV serology status, was performed. A stratification moment (STRm) was established when patients were pseudo-randomized to either arm (NTZ continuation if JCV negativity, or change to OCR if JCV positivity). Primary endpoints include time to first relapse and presence of relapses after STRm and OCR initiation. Secondary endpoints include clinical and radiological outcomes after 1\u00a0year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 67 patients included, 40 continued on NTZ (60%) and 27 were changed to OCR (40%). Baseline characteristics were similar. Time to first relapse was not significantly different. Ten patients in the JCV\u2009+\u2009OCR arm presented a relapse after STRm (37%), four during the washout period, and 13 patients in the JCV-NTZ arm (32.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.701). No differences in secondary endpoints were detected in the first year after STRm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The JCV status can be used as a natural experiment to compare treatment arms with a low selection bias. In our study, switching to OCR versus NTZ continuation led to similar disease activity outcomes.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-11645-x","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:23:49Z","timestamp":1679869429000},"page":"2559-2566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment"],"prefix":"10.1007","volume":"270","author":[{"given":"Albert","family":"Mu\u00f1oz-Vendrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-4850","authenticated-orcid":false,"given":"Pablo","family":"Arroyo-Pereiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Matas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Mart\u00ednez-Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Romero-Pinel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"9","key":"11645_CR1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"issue":"9","key":"11645_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon \u03b2-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911\u2013923. https:\/\/doi.org\/10.1056\/NEJMoa044396","journal-title":"N Engl J Med"},{"key":"11645_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007621.pub2","volume":"10","author":"E Pucci","year":"2011","unstructured":"Pucci E, Giuliani G, Solari A et al (2011) Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 10:CD007621. https:\/\/doi.org\/10.1002\/14651858.CD007621.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"11645_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","volume":"9","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Lang S, Wolff R et al (2020) A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther 9(2):359\u2013374. https:\/\/doi.org\/10.1007\/s40120-020-00212-5","journal-title":"Neurol Ther"},{"issue":"20","key":"11645_CR5","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870\u20131880. https:\/\/doi.org\/10.1056\/NEJMoa1107829","journal-title":"N Engl J Med"},{"issue":"8","key":"11645_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","volume":"10","author":"L Kappos","year":"2011","unstructured":"Kappos L, Bates D, Edan G et al (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10(8):745\u2013758. https:\/\/doi.org\/10.1016\/S1474-4422(11)70149-1","journal-title":"Lancet Neurol"},{"issue":"6","key":"11645_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0b013e318245d2d0","volume":"78","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Rudick RA (2012) Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 78(6):436\u2013437. https:\/\/doi.org\/10.1212\/WNL.0b013e318245d2d0","journal-title":"Neurology"},{"issue":"3","key":"11645_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon \u03b2-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"issue":"6","key":"11645_CR9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","volume":"78","author":"A Patel","year":"2021","unstructured":"Patel A, Sul J, Gordon ML et al (2021) Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol 78(6):736\u2013740. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0627","journal-title":"JAMA Neurol"},{"issue":"2","key":"11645_CR10","doi-asserted-by":"publisher","first-page":"205521732110138","DOI":"10.1177\/20552173211013831","volume":"7","author":"Z van Lierop","year":"2021","unstructured":"van Lierop Z, Toorop AA, Coerver E et al (2021) Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. Mult Scler J Exp Transl Clin 7(2):20552173211013830. https:\/\/doi.org\/10.1177\/20552173211013831","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"5","key":"11645_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/1352458520946017","volume":"27","author":"CR Mancinelli","year":"2021","unstructured":"Mancinelli CR, Scarpazza C, Cordioli C et al (2021) Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Mult Scler 27(5):790\u2013794. https:\/\/doi.org\/10.1177\/1352458520946017","journal-title":"Mult Scler"},{"issue":"2","key":"11645_CR12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","volume":"18","author":"A Zangh\u00ec","year":"2021","unstructured":"Zangh\u00ec A, Gallo A, Avolio C et al (2021) Exit strategies in natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study. Neurotherapeutics 18(2):1166\u20131174. https:\/\/doi.org\/10.1007\/s13311-021-01037-2","journal-title":"Neurotherapeutics"},{"issue":"6","key":"11645_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000297","volume":"3","author":"C Papeix","year":"2016","unstructured":"Papeix C, Vukusic S, Casey R et al (2016) Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm 3(6):e297. https:\/\/doi.org\/10.1212\/NXI.0000000000000297","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"11645_CR14","doi-asserted-by":"publisher","first-page":"175628641983780","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809. https:\/\/doi.org\/10.1177\/1756286419837809","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"11645_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","volume":"71","author":"M Cohen","year":"2014","unstructured":"Cohen M, Maillart E, Tourbah A et al (2014) Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 71(4):436\u2013441. https:\/\/doi.org\/10.1001\/jamaneurol.2013.6240","journal-title":"JAMA Neurol"},{"issue":"14","key":"11645_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","volume":"82","author":"VG Jokubaitis","year":"2014","unstructured":"Jokubaitis VG, Li V, Kalincik T et al (2014) Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82(14):1204\u20131211. https:\/\/doi.org\/10.1212\/WNL.0000000000000283","journal-title":"Neurology"},{"key":"11645_CR17","first-page":"9","volume":"XIV","author":"L Nass Kunstmann","year":"2008","unstructured":"Nass Kunstmann L, Manuel Merino JE (2008) Natural experiment as a new quasi-experimental design in social and health-related sciences. Ciencia y Enfermer\u00eda XIV:9\u201312","journal-title":"Ciencia y Enfermer\u00eda"},{"issue":"2","key":"11645_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"issue":"2","key":"11645_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"8","key":"11645_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","volume":"55","author":"C Confavreux","year":"1992","unstructured":"Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55(8):671\u2013676. https:\/\/doi.org\/10.1136\/jnnp.55.8.671","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"19","key":"11645_CR21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin CA, Khera AV, Kathiresan S (2017) Mendelian randomization. JAMA 318(19):1925\u20131926. https:\/\/doi.org\/10.1001\/jama.2017.17219","journal-title":"JAMA"},{"issue":"2","key":"11645_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s13311-022-01202-1","volume":"19","author":"F Rollot","year":"2022","unstructured":"Rollot F, Couturier J, Casey R et al (2022) Comparative effectiveness of natalizumab versus anti-CD20 in highly active relapsing-remitting multiple sclerosis after fingolimod withdrawal. Neurotherapeutics 19(2):476\u2013490. https:\/\/doi.org\/10.1007\/s13311-022-01202-1","journal-title":"Neurotherapeutics"},{"issue":"6","key":"11645_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ene.12988","volume":"23","author":"A Vennegoor","year":"2016","unstructured":"Vennegoor A, van Rossum JA, Leurs C et al (2016) High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol 23(6):1079\u20131085. https:\/\/doi.org\/10.1111\/ene.12988","journal-title":"Eur J Neurol"},{"key":"11645_CR24","doi-asserted-by":"publisher","first-page":"175628642199891","DOI":"10.1177\/1756286421998915","volume":"14","author":"CM Dwyer","year":"2021","unstructured":"Dwyer CM, Jokubaitis VG, Stankovich J et al (2021) High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. Ther Adv Neurol Disord 14:1756286421998915. https:\/\/doi.org\/10.1177\/1756286421998915","journal-title":"Ther Adv Neurol Disord"},{"issue":"19","key":"11645_CR25","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1212\/WNL.0b013e3182735c7a","volume":"79","author":"D Centonze","year":"2012","unstructured":"Centonze D, Rossi S, Rinaldi F, Gallo P (2012) Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 79(19):2004\u20132005. https:\/\/doi.org\/10.1212\/WNL.0b013e3182735c7a","journal-title":"Neurology"},{"key":"11645_CR26","first-page":"353","volume":"22","author":"L Romero-Pinel","year":"2016","unstructured":"Romero-Pinel L, Matas E, Bau L et al (2016) NEDA after stratification of PML risk. Multi Scler J 22:353 (Poster Session I)","journal-title":"Multi Scler J"},{"issue":"10","key":"11645_CR27","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1177\/1352458520969145","volume":"27","author":"M Cohen","year":"2021","unstructured":"Cohen M, Mondot L, Bucciarelli F et al (2021) BEST-MS: a prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Multi Scler 27(10):1556\u20131563. https:\/\/doi.org\/10.1177\/1352458520969145","journal-title":"Multi Scler"},{"issue":"8","key":"11645_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","volume":"86","author":"L Barbin","year":"2016","unstructured":"Barbin L, Rousseau C, Jousset N et al (2016) Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology 86(8):771\u2013778. https:\/\/doi.org\/10.1212\/WNL.0000000000002395","journal-title":"Neurology"},{"issue":"6","key":"11645_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/1352458518768433","volume":"24","author":"J Lorscheider","year":"2018","unstructured":"Lorscheider J, Benkert P, Lienert C et al (2018) Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. Multi Scler 24(6):777\u2013785. https:\/\/doi.org\/10.1177\/1352458518768433","journal-title":"Multi Scler"},{"key":"11645_CR30","doi-asserted-by":"crossref","unstructured":"Butzkueven H, Spelman T, Ozakbas S (2022) Real-world comparative effectiveness and persistence of cladribine tablets and other oral disease-modifying treatments for multiple sclerosis from GLIMPSE: results from the MSBase registry. Presented at ACTRIMS Forum. P342","DOI":"10.1177\/13524585221137502"},{"key":"11645_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102769","volume":"49","author":"H Bartosik-Psujek","year":"2021","unstructured":"Bartosik-Psujek H, Kaczy\u0144ski \u0141, G\u00f3recka M et al (2021) Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis\u2014a systematic review and network meta-analysis. Multi Scler Relat Disord 49:102769. https:\/\/doi.org\/10.1016\/j.msard.2021.102769","journal-title":"Multi Scler Relat Disord"},{"issue":"9856","key":"11645_CR32","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"issue":"1","key":"11645_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/ene.15121","volume":"29","author":"CV Russo","year":"2022","unstructured":"Russo CV, Sacc\u00e0 F, Frau J et al (2022) A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol 29(1):257\u2013266. https:\/\/doi.org\/10.1111\/ene.15121","journal-title":"Eur J Neurol"},{"key":"11645_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06197-3","author":"K \u015aladowska","year":"2022","unstructured":"\u015aladowska K, Kawalec P, Holko P, Osiecka O (2022) Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-022-06197-3","journal-title":"Neurol Sci"},{"issue":"5","key":"11645_CR35","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/brain\/awac064","volume":"145","author":"T Ruck","year":"2022","unstructured":"Ruck T, Barman S, Schulte-Mecklenbeck A et al (2022) Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain 145(5):1711\u20131725. https:\/\/doi.org\/10.1093\/brain\/awac064","journal-title":"Brain"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11645-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T13:10:17Z","timestamp":1682428217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11645-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["11645"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11645-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM-V, PAP, IL, LB, EM, AM-Y, SM-Y, and LR-P received honoraria compensation to participate in advisory boards, collaborations as a consultant, and scientific communications, and received research support and funding for travel and congress expenses from Biogen Idec, Novartis, TEVA, BMS, Horizon, Merck Serono, Genzyme, Almirall, Bial, Kern Pharma, Lilly, Sanofi, Bayer, and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Hospital Universitari de Bellvitge Research Ethics Committee, with reference EOM031\/22. Patients signed informed consent forms, and data were collected anonymously. Patient information confidentiality was handled in accordance with Spanish regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standard"}}]}}